Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2004

View Archived Issues

Incara receives approval for phase II SBIR grant for catalytic antioxidant work

Enrollment concludes in TAXUS V study

Millennium and NCI to study link between ACE2 and SARS

Long-term effects of Diamyd in patients with autoimmune diabetes

Decitabine delays progression to AML in patients with myelodysplastic syndromes

TLK-286 increases the efficacy of antitumor drugs in vitro

Antitumor effects of the chemosensitizer phenoxodiol in prostate and ovarian cancer

Dual PPARalpha/gamma agonist effective against metabolic syndrome in vivo

Integrin antagonists show good potency, selectivity and bioavailability

Novel integrin antagonist may be effective for post-PCI restenosis

New DPP-IV inhibitors prepared and tested by Eisai researchers

Axxima claims new inhibitors of herpes virus UL97 kinase

Novel protein kinase inhibitors in early development at Vertex

Two series of Itk inhibitors recently claimed by AstraZeneca

AstraZeneca scientists develop new alpha7 nAchR agonists

Inhibitors of CDK2 and other kinases emerge from Cyclacel R&D

CX-3543, a novel c-Myc oncogene inhibitor, shows efficacy in vivo

RS-5444, a PPARgamma agonist, shows high affinity against thyroid tumor growth

Promising tubulin-binding compound with antimitotic activity

DynPort develops tularemia vaccine under NIAID award

Germany approves ezetimibe/simvastatin for hypercholesterolemia

Primovist receives approval in Sweden

Ardana acquires global rights to Teverelix

Improvement in survival indicated in phase IIb trial of L-BLP-25

Clofarabine NDA submission completed

First preclinical data on MEK inhibitor ARRY-142886 presented

ZymoGenetics cleared to commence phase I study of IL-21

Broad activity of cell cycle inhibitor SNS-595 in cancer models

Enrollment commences in MEND-CABG trial of MC-1

Cardizem approved for chronic stable angina

QR-336 protects mice in a lethal-dose radiation study

DSMB recommends dosing of final patients in VRX-496 phase I trial

AP-23464 effective against imatinib-resistant leukemia cells

Aventis Supervisory Board recommends negotiation of tie-up with Novartis